Dec 10, 2019
Answer ALS and Avanade harness technology to accelerate largest-ever ALS research program
Dec 09, 2019
Muscular Dystrophy Association Names Sharon Hesterlee, Ph.D., Executive Vice President, Chief Research Officer
Dec 04, 2019
New ALS Association Partnership with ALS Investment Fund Targets $100 Million in New Funding for ALS Therapeutic Development
Nov 21, 2019
Major Research Funding for Blood Test to Accelerate Clinical Trials for New Frontotemporal Degeneration (FTD) Therapies
Nov 21, 2019
Muscular Dystrophy Association to host first Patient Focused Drug Development Meeting for Pompe Disease March 9, 2020 in Washington D.C.
Nov 18, 2019
Kadimastem Intends to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol Following Recent Positive Interim Results
Nov 11, 2019
Kadimastem to Present Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv, Israel
Oct 24, 2019
Fourth Annual AFTD Benefit Raises More Than $2 Million in Support of Frontotemporal Degeneration Research, Support and Awareness
Oct 23, 2019
ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
Oct 14, 2019
Collaborative Medicinal Development Enrolls First Patient In a Randomized, Placebo-Controlled Clinical Trial of CuATSM For The Treatment of Amyotrophic Lateral Sclerosis
Oct 07, 2019
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
Sep 20, 2019
Mitsubishi Tanabe Pharma America To Present On ALS Clinical Programs At 2019 Muscle Study Group Annual Scientific Meeting
Sep 18, 2019
Clene Nanomedicine, Inc. Announces Selection of CNM-Au8 for the Harvard Led HEALEY ALS Platform Trial, a Clinical Trial for Amyotrophic Lateral Sclerosis
Sep 18, 2019
Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
Sep 17, 2019
Clene Nanomedicine, Inc. Awarded $1.37M AUD Grant from FightMND to Conduct Phase 2 Clinical Study for the Treatment of Amyotrophic Lateral Sclerosis
Sep 03, 2019
Muscular Dystrophy Association Launches "MDA National Muscular Dystrophy Awareness Month" as Part of Multi-Faceted Campaign Celebrating Extensive Strides in Science and Care
Aug 27, 2019
Burn Boot Camp Raises $523,690 Through Second Annual National "Be Their Muscle" Fundraiser Event
Aug 02, 2019
Jiffy Lube® Teams Up with MDA for Annual MUSCLE UP!(SM) Campaign to Transform the Lives of Kids and Adults with Neuromuscular Diseases
Jul 22, 2019
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
Jul 16, 2019
Mallinckrodt Halts Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)